Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Abroad (travel likely)RecruitingPHASE2

Conditions

Fuchs Endothelial Corneal Dystrophy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Contact: Study coordinator (Ula Jurkunas, MD) · Ula_Jurkunas@meei.harvard.edu · 6175734330
Contact: Study coordinator (Michael Cheung, MSc. CCRP) · mcheung0@meei.harvard.edu · 6175736060
Contact: Principal Investigator (Ula Jurkunas, MD)

Study leads

Ula Jurkunas, MD
Principal Investigator
Mass Eye and Ear

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Fuchs Endothelial Corneal Dystrophy · Fuchs

Abroad (travel likely)RecruitingPHASE2

Indianapolis, United States · Grand Rapids, United States

Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy

Fuchs Endothelial Corneal Dystrophy

Abroad (travel likely)Recruiting

Saint-Etienne, France · Metz, France

Descemet Endothelial Thickness Comparison Trial II

Fuchs · Fuchs Dystrophy · Fuchs' Endothelial Dystrophy

Abroad (travel likely)RecruitingPHASE3

Palo Alto, United States · Sacramento, United States

Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK)

Fuchs Endothelial Corneal Dystrophy · Descemet Membrane Endothelial Keratoplasty (DMEK)

Abroad (travel likely)Recruiting

Heidelberg, Germany